Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 9/20 | 1.00 |
| ▸ | MDM4 | O15151 | 1/20 | 1.00 |
| ▸ | BCL2L11 | O43521 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | BAX | Q07812 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | BECN1 | Q14457 | 1/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 1.00 |
| ▸ | BAD | Q92934 | 1/20 | 1.00 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.88 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.88 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.88 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.88 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt 737 SCHEMBL158942 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL29355185 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL1541072 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540670 | 0.97 | BCL2L1 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540214 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540387 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540510 | 0.96 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540736 | 0.96 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1541579 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL26648550 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138261-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-11-12 | — | — | US | claimed |
| US-20220143135-A1 | INHIBITORS OF BCL-2 | UNIV CASE WESTERN RESERVE (US) | 2022-05-12 | — | — | US | claimed |
| US-11229641-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-25 | — | — | US | claimed |
| US-11230579-B2 | Method of treating BCL-2 over-expressing disorders using arts containing a BH3-like domain | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2022-01-25 | — | — | US | claimed |
| WO-2019243236-A1 | NEW ANTICANCER DRUG COMBINATIONS | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2019-12-26 | — | — | WO | claimed |
| EP-2814839-B1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL HAIFA UNIV ECONOMIC CORPORATION LTD (IL) | 2019-08-28 | — | — | EP | claimed |
| US-10058588-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-08-28 | — | — | US | claimed |
| US-20180207164-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-07-26 | — | — | US | claimed |
| US-20180161391-A1 | INHIBITORS OF BCL-2 | UNIV CASE WESTERN RESERVE (US) | 2018-06-14 | — | — | US | claimed |
| EP-3331531-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | Gilead Sciences, Inc. (US) | 2018-06-13 | — | — | EP | claimed |
| US-20170224678-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY | 2017-08-10 | — | — | US | claimed |
| US-9657073-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-05-23 | — | — | US | claimed |
| US-20170081380-A1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2017-03-23 | — | — | US | claimed |
| WO-2017023584-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-08-22 | — | — | US | claimed |
| US-8445441-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-21 | — | — | US | claimed |
| WO-2012031103-A2 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-03-08 | — | — | WO | claimed |
| US-20110312896-A1 | INHIBITORS OF BCL-2 | DISTELHORST CLARK W (US) | 2011-12-22 | — | — | US | claimed |
| US-8034779-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-10-11 | — | — | US | claimed |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224678-A1 | INHIBITORS OF BCL-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885BCL2 1/4885MDM4 2542/4885 |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | BCL2L1 3/4885BCL2 6/4885MDM4 1770/4885 |
| US-20180161391-A1 | INHIBITORS OF BCL-2 | BCLAF1, BCL2L1, BCL2L11 | BCL2L1 2/4885BCL2 8/4885MDM4 1195/4885 |
| US-20180207164-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BTK, SYK, BCL3 | BCL2L1 17/4885BCL2 20/4885MDM4 583/4885 |
| US-20110312896-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | BCL2L1 3/4885BCL2 6/4885MDM4 1770/4885 |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | BCLAF1, BCL2L1, BCL2L11 | BCL2L1 2/4885BCL2 8/4885MDM4 1195/4885 |
| US-11229641-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885BCL2 1/4885MDM4 2542/4885 |
| US-12138261-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885BCL2 1/4885MDM4 2542/4885 |
| US-20220143135-A1 | INHIBITORS OF BCL-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885BCL2 1/4885MDM4 2542/4885 |
| US-10058588-B2 | Inhibitors of BCL-2 | BCLAF1, BCL2L1, BCL2L11 | BCL2L1 2/4885BCL2 8/4885MDM4 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.